Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gland Pharma (NSE:GLAND) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Gland Pharma Forward PE Ratio Related Terms
Gland Pharma Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Gland Pharma's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gland Pharma Forward PE Ratio Chart
Gland Pharma Annual Data
Trend
2025-03
2026-03
Forward PE Ratio
26.64
24.11
Gland Pharma Quarterly Data
2021-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
53.19
27.85
26.64
30.88
33.29
22.18
24.11
NSE:GLAND vs ZTS, UTHR: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gland Pharma Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Gland Pharma's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Gland Pharma (NSE:GLAND) has a Forward PE Ratio of 33.64 as of Jul. 18, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Gland Pharma and its competitors. According to the industry distribution chart, Gland Pharma ranks #319 out of 410 companies in the Drug Manufacturers industry, placing it in the top 77.8%.
Is Gland Pharma's Forward PE Ratio too high?
Gland Pharma's current Forward PE Ratio is 33.64. The Drug Manufacturers industry median Forward PE Ratio is 17.27. Gland Pharma's value of 33.64 is 94.8% above this industry median. Based on the distribution chart, Gland Pharma ranks #319 out of 410 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Gland Pharma has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Forward PE Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gland Pharma ranks #319 out of 410 companies for Forward PE Ratio. This places Gland Pharma in the lower half of its industry. The industry median Forward PE Ratio is 17.27. Gland Pharma's value of 33.64 is 94.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.27, based on 410 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gland Pharma's current Forward PE Ratio of 33.64 is 94.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Gland Pharma and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gland Pharma's current Forward PE Ratio is 33.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,141.70, compared to a current price of ₹2,449.00 — trading 14.3% above its estimated fair value. The current Forward PE Ratio is 33.64 and 94.8% above the Drug Manufacturers industry median of 17.27. Gland Pharma's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current Forward PE Ratio is 33.64 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gland Pharma (NSE:GLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued.
The current stock price of ₹2,449.00 is trading 14.3% above its estimated GF Value™ of ₹2,141.70.
GuruFocus considers Gland Pharma to be Modestly Overvalued.
Key valuation signals for NSE:GLAND:
Forward PE Ratio: 33.64
GF Value™: ₹2,141.70 vs. price of ₹2,449.00 (14.3% above fair value)
Industry Position: 94.8% above the Drug Manufacturers median (#319 of 410)
No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
84GF Score
Get the complete analysis for NSE:GLAND
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAND has been successfully added to your 
